Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study

Chin Med J (Engl). 2022 Nov 5;135(21):2623-2624. doi: 10.1097/CM9.0000000000002047.

Authors

Yuankai Sun¹, Jiajia Wang¹, Yulu Qiu¹, Shiyu Lin¹, Fang Wang², Wenfeng Tan¹

Affiliations

¹ Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
² Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Axial Spondyloarthritis*
Humans
Spondylarthritis* / drug therapy
Treatment Outcome

Substances

secukinumab
Antibodies, Monoclonal, Humanized